e-Drug3D

1594

OMACETAXINE MEPESUCCINATE

DISCONTINUED

INN
OMACETAXINE MEPESUCCINATE

cas 26833-87-4

CLASS

ANTINEOPLASTIC
TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML)
PROTEIN SYNTHESIS INHIBITOR
OMACETAXINE MEPESUCCINATE BINDS TO THE A-SITE CLEFT IN THE PEPTIDYL-TRANSFERASE CENTER OF THE LARGE RIBOSOMAL SUBUNIT FROM A STRAIN OF ARCHAEABACTERIA
HYDROLYZED TO 4-DMHHT VIA PLASMA ESTERASES

ROUTE (list)

SUBCUTANEOUS

ATC code

L01XX40

PK parameters

VD 141 LITER
Cl 16.3 LITER / HOUR (EQN)
PPB 50 PERCENT
t1/2 6 HOUR

Target

TARGET RIBOSOME

PDB
OBSOLETE (- 4UL7 CRYSTAL STRUCTURE OF HOMOHARRINGTONINE BOUND TO THE YEAST 80S RIBOSOME)

Ligand code = HMT (link to the list of PDB complexes)

Download experimental 3D coordinates of HMT with added hydrogens

DrugCentral

Unknown

Download SDF file

Cephalotaxine, 3-[4-methyl (2R)-2-hydroxy-2-(4-hydroxy-4-methylpentyl)butanedioate]

Formula:
C29H39NO9

Calculated chemical properties:

MW 545.61
NB_atoms 39
XLogP 2.58
PSA 122.776
NB_HD 2
NB_HA 10
fsp3 0.66
Lipinski(0=no;1=yes) 0

FDA
NDA 203585 (pdf not found) INN (OMACETAXINE MEPESUCCINATE) SYNRIBO (TEVA PHARMS INTL) APPROVAL= AP YEAR= 2012 NEWMOLECULARENTITY DISCONTINUED